Sarepta Therapeutics Inc
SRPT
Company Profile
Business description
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Contact
215 First Street
Suite 415
CambridgeMA02142
USAT: +1 617 274-4000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
835
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 16.10 | -0.18% |
| CAC 40 | 8,235.72 | 95.32 | -1.14% |
| DAX 40 | 24,270.87 | 146.93 | -0.60% |
| Dow JONES (US) | 49,318.76 | 123.80 | -0.25% |
| FTSE 100 | 10,498.09 | 110.99 | -1.05% |
| HKSE | 26,487.48 | 126.41 | 0.48% |
| NASDAQ | 24,388.08 | 16.31 | -0.07% |
| Nikkei 225 | 59,349.17 | 873.27 | 1.49% |
| NZX 50 Index | 12,932.33 | 26.66 | 0.21% |
| S&P 500 | 7,095.56 | 13.58 | -0.19% |
| S&P/ASX 200 | 8,949.40 | 20.10 | -0.22% |
| SSE Composite Index | 4,085.08 | 2.95 | 0.07% |